Join the Fulvestrant group to help and get support from people like you.
Fulvestrant News
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
FRIDAY, June 20, 2025 – Nearly 40 percent of women with stage I breast cancer and two-thirds with stage II decide to extend endocrine therapy, according to a study published recently in JNCI:...
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
THURSDAY, Oct. 31, 2024 – Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated,...
Faslodex (fulvestrant) Receives FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
August 28, 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor...
FDA Approves New Dosing for Faslodex (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of Faslodex (fulvestrant) Injection,...
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer